Director/PDMR Shareholding
On October 16, 2025, Theracryf PLC announced that Northern Standard Limited, a company with a 49% interest held by Non-Executive Director Ed Wardle, purchased 7,342,296 ordinary shares. The shares, priced at £0.00175 each, are ordinary shares of 0.25 pence each. Following this transaction on October 14, 2025, Mr. Wardle is now deemed to have an interest in 430,069,568 Ordinary Shares, representing 20.01% of the company's issued Ordinary Shares.
Select text to share a quote on X · sign in to keep highlights & notes in your TCF notes
Alderley Park, UK - 16 October 2025: TheraCryf plc (AIM: TCF), the clinical stage drug development company focussing on brain disorders, announces that Northern Standard Limited, a company that Non-Executive Director, Ed Wardle, has a 49 per cent interest in purchased 7,342,296 ordinary shares of 0.25 pence each in the Company ("Ordinary Shares") on 14 October 2025 at a price of £0.00175 and now owns 430,069,568 Ordinary Shares.
As a result, Mr Wardle is deemed to have an interest in 430,069,568 Ordinary Shares, representing 20.01 per cent of the Company's issued Ordinary Shares.
| 1. | Details of PDMR / person closely associated with them ("PCA") | |||||
| a) | Name | Edward James Norman Wardle | ||||
| b) | Position / status | Non Executive Director | ||||
| c) | Initial notification / amendment | Initial notification | ||||
| a) | Description of the financial instrument | Theracryc PLC | ||||
| b) | Nature of the transaction | Acquisition of ordinary shares by Northern Standard Limited, a company that Edward James Norman Wardle has 49% ownership of | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information - Aggregated volume - Price | See above | ||||
| e) | Date of the transaction | 14 October 2025 | ||||
| f) | Place of the transaction | Outside a trading venue |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.